Clinical trials: Positron-Emission Tomography
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT01333033
- Testing
- Oxaliplatin, Leucovorin Calcium, Fluorouracil
- Where
- 68 sites in United States
- Volunteers
- 257 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Healthy Volunteers, Alzheimer Disease
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric conditions such as depression and addiction, along with…
- Conditions
- Healthy Volunteers, Alzheimer Disease, Molecular Imaging
- Trial name
- I2PETHV (NCT02323217)
- Testing
- [11C]BU99008, Idazoxan, Isocarboxazid
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Idiopathic Pulmonary Fibrosis
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
- Trial name
- IPF-201 (NCT04072315)
- Testing
- PLN-74809, Knottin tracer
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pliant Therapeutics, Inc.
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00602043
- Testing
- F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Neurofibromatosis Type 1, Precancerous Condition
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a…
- Trial name
- NCT00060008
- Testing
- fludeoxyglucose F 18, gadopentetate dimeglumine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital of Philadelphia
Heart Failure, Type 2 Diabetes Mellitus
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and…
- Trial name
- Protocol1 (NCT03560323)
- Testing
- Beta-hydroxy-butyrate
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Dexmedetomidine Induced Sedation
Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep
The investigators are doing this research study to find out how and where dexmedetomidine, a sedative anesthetic, acts in the brain.
- Trial name
- NCT01485380
- Testing
- dexmedetomidine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer…
- Trial name
- NCT01190566
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Seoul National University Hospital
Prostate Neoplasm
F-18 Sodium Fluoride in Prostate Cancer
Background: Sodium fluoride (NaF) is a common compound that is found in various foods and can be used to increase bone strength.
- Trial name
- NCT01240551
- Testing
- F-18 NaF
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Alzheimer's Disease
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
- Trial name
- NCT01703702
- Testing
- florbetapir (18F)
- Where
- 57 sites in United States, France and 1 more
- Volunteers
- 641 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
18F-AV-1451 Autopsy Study
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
- Trial name
- NCT02516046
- Testing
- Flortaucipir F18, PET Scan
- Where
- 31 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- Avid Radiopharmaceuticals
Prostate Cancer, High Risk
68 Ga-PSMA for High Risk Prostate Cancer
This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence.
- Trial name
- NCT04614363
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Methodist Hospital Research Institute
Schizophrenia
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs.
- Trial name
- BEST (NCT00712270)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kettering Health Network
Breast Carcinoma
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
This clinical trial studies positron emission tomography imaging in using copper Cu 64 TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography…
- Trial name
- NCT02810873
- Testing
- Positron Emission Mammography, Positron Emission Tomography, Fludeoxyglucose F-18
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Neuroendocrine Tumors
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
- Trial name
- NCT02609737
- Testing
- PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to…
- Trial name
- NCT03927209
- Testing
- BI 1467335
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Recurrent Colon Cancer, Recurrent Rectal Cancer
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer
- Trial name
- NCT01821105
- Testing
- PET Scan, CT Scan, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Depression, HIV Infections
PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects
Background: Human immunodeficiency virus (HIV) infection is a serious disease with no cure. Some people with HIV have depression and other mood problems. They can have problems with thinking and memory.
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Trial name
- NCT03581305
- Testing
- 18F-FDOPA, 11C-DASB
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neuroendocrine Neoplasms
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
The purpose of this study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in…
- Trial name
- NCT06240741
- Testing
- [68Ga]Ga-DOTA-TATE, 68Ge/68Ga Generator
- Where
- 8 sites in Japan
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals